PEDIATRIC VACCINES MARKET ANALYSIS

Regional Analysis

Global Pediatric Vaccines Market- Regional Analysis

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa

Among region, North America is expected to dominate the market over the forecast period, due to increasing vaccines approvals by regulatory authorities in region, and this is expected to drive the market growth over the forecast period. For instance, on June 18, 2022, the Centers for Disease Control and Prevention (CDC) approved COVID-19 vaccination for young children aged 6 months old that means around 20 million children in the U.S. are under 5 yearsof age, and are eligible for vaccination.

Europe region is expected to be the second largest region over the forecast period, owing to increasing product grants by regulatory authorities for usage of vaccine in pediatric population in the region, in order to expand their product portfolio is expected to drive the market growth over the forecast period. For instance, on February 24, 2022, European Medicines Agency’s human medicines committee (CHMP) granted an extension of indication for the COVID-19 vaccine Spikevax for usage in children of age 6 to 11 years. The vaccine is developed by Moderna, is a pharmaceutical and biotechnology company and is already approved for usage in adults and children age 12 years and above.